NovaBridge Biosciences NBP
NASDAQ NBP
$1.37 -0.05 (-3.86%)
At close: Oct 21, 2026 · 4:00 PM EDT

NovaBridge Biosciences (NBP) EBITDA Margin (2020)

Updated

NovaBridge Biosciences (NBP) recorded EBITDA Margin of -30761.42% in FY2023, down 12099.66 percentage points from -18661.76% in FY2022.

Analysis

NovaBridge Biosciences (NBP) EBITDA Margin (2020) Analysis & Trends

Starting with FY2017, NovaBridge Biosciences' EBITDA Margin history includes 7 years.

  • Annual EBITDA Margin has declined for three straight years, with a five-year change of -29958.36 percentage points (FY2018 to FY2023).
  • The FY2023 figure is the lowest annual EBITDA Margin in data going back to FY2017.
  • Per Business Quant data, NBP's EBITDA Margin was -18661.76% in FY2022 (-16353.34 pp), -2308.42% in FY2021 (-2304.03 pp), -4.39% in FY2020 (+4846.34 pp) and -4850.73% in FY2019 (-4047.66 pp).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 35.95%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 49.01%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 6.02%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 33.11%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 46.01%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -124.26%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 39.16%
10 NovaBridge Biosciences 131.20 Mn -664.38 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 60.57%
API Access

NovaBridge Biosciences EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=NBP&period=max&api_key=YOUR_API_KEY